In this issue of Diabetes Care, Linnebjerg et al. (1) compare the pharmacokinetics (PK) and pharmacodynamics (PD) of a Lilly synthetized insulin glargine (LY IGlar) with the insulin glargine Lantus (IGlar) based on a series of clamp studies in healthy volunteers and conclude for PK/PD that there is similarity of the LY IGlar vs. IGlar. The strengths of the study should be discussed along with its limitations.

How to accurately establish pharmacokinetics/ pharmacodynamics of long- Acting insulins in humans: Relevance to biosimilar insulins

PORCELLATI, Francesca;LUCIDI, Paola;BOLLI, Geremia Brunetto;FANELLI, Carmine Giuseppe
2015

Abstract

In this issue of Diabetes Care, Linnebjerg et al. (1) compare the pharmacokinetics (PK) and pharmacodynamics (PD) of a Lilly synthetized insulin glargine (LY IGlar) with the insulin glargine Lantus (IGlar) based on a series of clamp studies in healthy volunteers and conclude for PK/PD that there is similarity of the LY IGlar vs. IGlar. The strengths of the study should be discussed along with its limitations.
2015
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1402891
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact